Ambu recalls resuscitation product
The Danish company is recalling a resuscitation product, reports Bloomberg News after a Danish Medicines Authority announcement.
MedWatch
A part of Watch Media
The Danish company is recalling a resuscitation product, reports Bloomberg News after a Danish Medicines Authority announcement.
Sanofi ends development of Covid Messenger-RNA vaccine.
One of the drugs Sanofi had otherwise imagined would become one of the stars in the autoimmune medication portfolio has flunked out of phase III trials as a treatment for skin disease pemfigus.
In a reform proposal on Tuesday, the Danish government announced plans to make the 130 percent raised tax deduction on research and development permanent. A cap on the tax value of individual companies will still be in place, however.
The case of the missing delivery of Covid-19 vaccines won't make it to court as the two parties agree to settle.
A new phase III study conducted by Pfizer comparing its drug abrocitinib with Sanofi best-seller Dupixent favors the former's medicine.
Demand for medication production is now so high that AGC Biologics' Danish unit expects to sell the output of almost full production capacity at the company's new factory within three years after commissioning, expectedly in 2023.
The Danish pharmaceutical firm is the latest of several companies operating in the US to close its doors to unvaccinated personnel.
It is not just in the US that significant demand for Novo Nordisk's obesity drug Wegovy is having an impact. The pharmaceutical firm now reports that new launches of the drug will not take place until during the second half of 2022.
A growth hormone for weekly use made by Denmark's Ascendis Pharma may now be commercialized in the US after the public authority approved the company's treatment, Skytrofa.
National Danish infectious disease research organization Statens Serum Institut has found a manufacturer for its in-house Covid-19 vaccine, moving it closer to testing the candidate on human subjects following a series of delays.
In a long-awaited phase II trial, Bavarian Nordic starts testing the efficacy of its Covid-19 vaccine for reinforcing existing immunity in persons either previously vaccinated or infected.
2020 revenue at Xellia Pharmaceuticals, a part of the Novo group, took a beating from the delayed commissioning of its US factory. Now, however, the first batch of medication has left the building.
After having taken a skeptical position on disclosing how much money Coloplast makes in each country where it operates, the company has now shifted its stance on the matter. Effective from the annual report's release in November, Denmark's largest medical technology company will be more transparent about its tax payments.
With the launch of hybrid product Jabra Enhance Plus, developed by GN Hearing alongside group affiliate GN Audio, the hope is to pry open a hitherto unaddressed market for people with mild hearing loss worth USD 50m solely in the US. However, it will be a long and tough process, notes GN Hearing CEO Gitte Aabo.
The Danish pharmaceutical company is exploring its options for how unvaccinated staff can return to work at Novo Nordisk's US headquarters in New Jersey and the office in Washington D.C.
Japanese Otsuka, Lundbeck's partner in sharing rights for Abilify Maintena, signals plans to seek marketing approval for a longer-acting version of the drug – a move that could extend the medication's patent protection.
Type 2 diabetes drug Jardiance has received the FDA's green light to treat chronic heart failure.
The US market plays a key role for all of Coloplast's business units, but the medical technology giant approaches the market in a different way and will only pursue acquisitions within two areas.
The hearing aid supplier notes a high level of growth in the second quarter of the year following last year's headwinds during the same period. However, despite revenue surging ahead, the operating margin underperforms, contrary to analyst estimates. GN Hearing maintains its financial outlook for the year.
While sales growth of Lundbeck's core products has stabilized well in Europe and international markets following Covid-19's peak, sales of several products in the US are still lagging – and the setback from Northera was bigger than foreseen.
All four of Coloplast's business divisions present growth in fiscal 2020-2021, prompting the medical tech firm to adjust its annual financial outlook.
The US-based pharmaceutical company has kicked off a big management reshuffle after a top-level decision ordered independent units for neuroscience and immunology, with the latter handling a potential launch of Alzheimer's drug donanemab.
Ambu's hurried construction plans, announced this summer, for a new endoscope factory in Mexico are tied mounting pressure in production capacity at the group's existing plant in Malaysia that struggled to keep up with demand.
Revenue will end up in the lower end of the spread Lundbeck forecast in early 2021, the Danish pharmaceutical firm informs after closing the first two quarters of this year.
(Senior) Drug Substance Specialist 
Production Director 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Client Talent Acquisition Specialist 
Biomarker Operations Lead 
Laboratory technician for process development and clinical manufacturing 
Clinical Trial Manager 
Senior Chemical Safety Advisor 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Director for innovative pre-clinical testing unit 
Consultant Manager Analytical Coordinator for Analytical Development Scientific Writer 
Biostatistician 
Communications Consultant 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Clinical Trial Manager for development of in vitro diagnostics 
IRT Manager, Clinical Drug Supply 
Nordic Medical Affairs Manager Director of Toxicology Project Manager & Scrum Master Senior IT Network Engineer Innovation Project Manager, Display Unit Clinical Trial Administrator 
Key Account Manager, Europe and Asia